The Latin America, Middle East and Africa Peptide Therapeutics Market is expected to witness market growth of 12.5% CAGR during the forecast period (2022-2028).
O-glycosylation takes place in threonine or serine residues, where the oxygen molecule on the side chain forms an ether bond with the carbohydrate. Chemical glycosylation is a type of non-natural glycosylation that involves the binding of carbohydrate units to distinct amino acid residues at the peptide's N-terminus. Chemo-enzymatic glycosylation is another method of glycosylation that involves the use of enzymes. This approach is employed in the synthesis of complicated chemicals. Glycol-peptides and glycoproteins can be synthesized via chemical and chemo-enzymatic techniques. Cyclization can also be utilized to reduce proteolytic degradation and extend half-life by stiffening the peptide shape to prevent enzymatic cleavage.
AIDS, tuberculosis, malaria, gastroenteritis, and hypertension are the most common health concerns in Africa. According to the National Library of Medicines, hypertension affects nearly 20% of the adult population. Renal illness, particularly glomerular disease, is more common in Africa, and it appears to be more severe than in Western countries. The nephrotic syndrome is the most common manner of presentation, with onset between the ages of five and eight years. Renal-related symptoms account for 2 to 3% of overall medical admissions in tropical nations, with glomerulonephritides accounting for the bulk.
In all African countries, there are no accurate statistics on ESRD. The South African Dialysis and Transplant Registry (SADTR) statistics represent patients who have been approved for renal replacement therapy (RRT) rather than the etiology of chronic renal failure (CRF), as public sector state facilities is expected to only provide RRT to patients who are transplant candidates.
The Brazil market dominated the LAMEA Peptide Therapeutics Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $1,273.3 million by 2028. The Argentina market is poised to grow at a CAGR of 13.1% during (2022-2028). Additionally, The UAE market is expected to display a CAGR of 12.2% during (2022-2028).
Based on Type, the market is segmented into Innovative and Generic. Based on Route of Administration, the market is segmented into Parenteral Route, Pulmonary, Mucosal, Oral Route, and Others. Based on Synthesis Technology, the market is segmented into Liquid Phase Peptide Synthesis (LPPS), Solid Phase Peptide Synthesis (SPPS), and Hybrid Technology. Based on Type of Manufacturers, the market is segmented into In-house and Outsourced. Based on Application, the market is segmented into Metabolic, Cardiovascular Disorder, GIT & Renal, Antiinfection & Dermatology, Respiratory, Central Nervous System, Cancer, Pain, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly And Company, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Lonza Group AG, and Amgen, Inc.
By Type
O-glycosylation takes place in threonine or serine residues, where the oxygen molecule on the side chain forms an ether bond with the carbohydrate. Chemical glycosylation is a type of non-natural glycosylation that involves the binding of carbohydrate units to distinct amino acid residues at the peptide's N-terminus. Chemo-enzymatic glycosylation is another method of glycosylation that involves the use of enzymes. This approach is employed in the synthesis of complicated chemicals. Glycol-peptides and glycoproteins can be synthesized via chemical and chemo-enzymatic techniques. Cyclization can also be utilized to reduce proteolytic degradation and extend half-life by stiffening the peptide shape to prevent enzymatic cleavage.
AIDS, tuberculosis, malaria, gastroenteritis, and hypertension are the most common health concerns in Africa. According to the National Library of Medicines, hypertension affects nearly 20% of the adult population. Renal illness, particularly glomerular disease, is more common in Africa, and it appears to be more severe than in Western countries. The nephrotic syndrome is the most common manner of presentation, with onset between the ages of five and eight years. Renal-related symptoms account for 2 to 3% of overall medical admissions in tropical nations, with glomerulonephritides accounting for the bulk.
In all African countries, there are no accurate statistics on ESRD. The South African Dialysis and Transplant Registry (SADTR) statistics represent patients who have been approved for renal replacement therapy (RRT) rather than the etiology of chronic renal failure (CRF), as public sector state facilities is expected to only provide RRT to patients who are transplant candidates.
The Brazil market dominated the LAMEA Peptide Therapeutics Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $1,273.3 million by 2028. The Argentina market is poised to grow at a CAGR of 13.1% during (2022-2028). Additionally, The UAE market is expected to display a CAGR of 12.2% during (2022-2028).
Based on Type, the market is segmented into Innovative and Generic. Based on Route of Administration, the market is segmented into Parenteral Route, Pulmonary, Mucosal, Oral Route, and Others. Based on Synthesis Technology, the market is segmented into Liquid Phase Peptide Synthesis (LPPS), Solid Phase Peptide Synthesis (SPPS), and Hybrid Technology. Based on Type of Manufacturers, the market is segmented into In-house and Outsourced. Based on Application, the market is segmented into Metabolic, Cardiovascular Disorder, GIT & Renal, Antiinfection & Dermatology, Respiratory, Central Nervous System, Cancer, Pain, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly And Company, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Lonza Group AG, and Amgen, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Innovative
- Generic
- Parenteral Route
- Pulmonary
- Mucosal
- Oral Route
- Others
- Liquid Phase Peptide Synthesis (LPPS)
- Solid Phase Peptide Synthesis (SPPS)
- Hybrid Technology
- In-house
- Outsourced
- Metabolic
- Cardiovascular Disorder
- GIT & Renal
- Antiinfection & Dermatology
- Respiratory
- Central Nervous System
- Cancer
- Pain
- Others
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Eli Lilly And Company
- AstraZeneca PLC
- Teva Pharmaceuticals Industries Ltd.
- Novartis AG
- Pfizer, Inc.
- Sanofi S.A.
- GlaxoSmithKline PLC
- Takeda Pharmaceutical Company Limited
- Lonza Group AG
- Amgen, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. LAMEA Peptide Therapeutics Market by Type
Chapter 5. LAMEA Peptide Therapeutics Market by Route of Administration
Chapter 6. LAMEA Peptide Therapeutics Market by Synthesis Technology
Chapter 7. LAMEA Peptide Therapeutics Market by Type of Manufacturers
Chapter 8. LAMEA Peptide Therapeutics Market by Application
Chapter 9. LAMEA Peptide Therapeutics Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- Eli Lilly And Company
- AstraZeneca PLC
- Teva Pharmaceuticals Industries Ltd.
- Novartis AG
- Pfizer, Inc.
- Sanofi S.A.
- GlaxoSmithKline PLC
- Takeda Pharmaceutical Company Limited
- Lonza Group AG
- Amgen, Inc.
Methodology
LOADING...
